文献速递免疫规划卫生政策与健康促进慢病防控与筛查

2剂与3剂乙肝疫苗在特定成人人群中预防的成本效果比较

Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations.
PubMed 文献 · Vaccine · 2021-05-21

该分析用健康经济学马尔可夫模型,从美国管理式医疗支付方视角比较2剂HEPLISAV-B与3剂Engerix-B在糖尿病、慢性肝病或肾病、终末期肾病、医务人员、旅行者和公共卫生人群中的成本效果。结果显示HEPLISAV-B在多个成人人群中具有有利的成本效果,在慢性肾病和终末期肾病人群中增量成本效果比占优,概率敏感性分析支持其稳健性。

要点

  • HEPLISAV-B在糖尿病、医务人员、旅行者和慢性肝病患者中成本效果有利。
  • 在慢性肾病和终末期肾病人群中HEPLISAV-B的增量成本效果比占优。
  • 概率敏感性分析支持上述成本效果结果的稳健性。

核心结论

  • HEPLISAV-B在美国推荐的多个成人人群中具有成本效果。

研究设计与样本

  • 采用健康经济学马尔可夫模型,纳入依从率、血清保护率、医疗成本和当前定价,从美国管理式医疗支付方视角估算终身支出与生存差异。

主要发现

  • HEPLISAV-B在糖尿病、医务人员、旅行者和慢性肝病患者中成本效果有利。
  • HEPLISAV-B在慢性肾病和终末期肾病患者中增量成本效果比占优。
  • 概率敏感性分析支持成本效果结果的稳健性。
  • 额外分析提示HEPLISAV-B在一般成人人群中具有成本效果。

临床怎么用

  • 可为美国推荐的乙肝疫苗接种成人人群选择2剂HEPLISAV-B提供成本效果依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The hepatitis B virus is highly infectious and can cause incurable liver disease, leading to high morbidity rates, increased healthcare utilization, and high mortality. Multiple preventative hepatitis B vaccine options have been available for decades, but adherence to the traditional 6-month vaccine schedule for the approved 3-dose series remains low in adult populations at risk of hepatitis B exposure. A 2-dose hepatitis B vaccine (HEPLISAV-B) approved by the US Food and Drug Administration in 2017 induces rapid seroprotection within 1 month and has a safety profile comparable to a commonly used 3-dose vaccine. In a previous cost-effectiveness study, HEPLISAV-B had a favorable cost-effectiveness profile for multiple at-risk populations. The goal of the current analysis was to update and extend previous findings by evaluating cost-effectiveness of HEPLISAV-B compared with a 3-dose vaccine (Engerix-B) in selected adult populations, including patients with diabetes, chronic liver or kidney disease, end-stage renal disease, healthcare personnel, travelers to countries with endemic hepatitis B, and a public health population. Cost-effectiveness was measured as incremental cost-effectiveness ratios using a health economics Markov model that accounts for adherence rates, seroprotection rates, healthcare costs, and current pricing considerations. Patients progressed between a series of health states, and the difference in lifetime spending and survival for individuals receiving either HEPLISAV-B or Engerix-B was estimated from the perspective of a US managed care payer, HEPLISAV-B had favorable cost-effectiveness profiles for patients with diabetes, healthcare personnel, travelers, and patients with chronic liver disease and dominant incremental cost-effectiveness ratios for patients with chronic kidney disease and end-stage renal disease. A probabilistic sensitivity analysis supported the robustness of the cost-effectiveness profiles, and an additional analysis indicated that HEPLISAV-B was cost-effective in the general adult population. Overall, HEPLISAV-B was cost-effective in multiple adult populations recommended for HBV vaccination in the United States.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hirst A, Hyer RN, Janssen RS, et al. Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations. Vaccine. 2021. PMID: 34030898. doi:10.1016/j.vaccine.2021.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。